Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 10/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 1.00 |
| ▸ | HPGD | P15428 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.73 |
| ▸ | USP2 | O75604 | 2/20 | 0.73 |
| ▸ | GLA | P06280 | 1/20 | 0.73 |
| ▸ | NPC1 | O15118 | 5/20 | 0.70 |
| ▸ | RAB9A | P51151 | 5/20 | 0.70 |
| ▸ | TP53 | P04637 | 3/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.68 |
| ▸ | PPARG | P37231 | 3/20 | 0.62 |
| ▸ | PPARD | Q03181 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Koparin SCHEMBL5723673 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDMAPT | |
| Khrinone E SCHEMBL31352025 | 0.90 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDMAPT | |
| Khrinone E SCHEMBL21168203 | 0.90 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDMAPT | |
| SCHEMBL27916248 | 0.89 | KDM4E (0.80) | KDM4EHSD17B10ALDH1A1HPGDMAPT | |
| SCHEMBL13669867 | 0.88 | KDM4E (0.85) | KDM4EHSD17B10ALDH1A1HPGDMAPT | |
| SCHEMBL234467 | 0.84 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDMAPT | |
| SCHEMBL17938790 | 0.84 | KDM4E (0.76) | KDM4EHSD17B10ALDH1A1HPGDMAPT | |
| SCHEMBL30991585 | 0.84 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDMAPT | |
| 2'-Methoxyformonetin SCHEMBL29777010 | 0.84 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDMAPT | |
| 2'-Methoxyformonetin SCHEMBL234355 | 0.84 | KDM4E (1.00) | KDM4EHSD17B10ALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4580612-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-07-09 | — | — | EP | claimed |
| US-12163004-B2 | Polymer composites | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2024-12-10 | — | — | US | claimed |
| WO-2024047248-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-03-07 | — | — | WO | claimed |
| EP-4746880-A2 | METHODS OF TREATING DILATED CARDIOMYOPATHY | Regencor, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122055354-A | Lipid compounds and related compositions and uses | 波西达治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | VTV THERAPEUTICS LLC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4580612-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-07-09 | — | — | EP | disclosed |
| WO-2025049925-A2 | LIPIDOID COMPOUNDS AND RELATED COMPOSITIONS AND USES | POSEIDA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20250051551-A1 | IMPROVED POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2025-02-13 | — | — | US | disclosed |
| WO-2025024320-A2 | METHODS OF TREATING DILATED CARDIOMYOPATHY | REGENCOR, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20240423967-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | ARES TRADING S.A. (CH) | 2024-12-26 | — | — | US | disclosed |
| US-20240101791-A1 | POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2024-03-28 | — | — | US | disclosed |
| WO-2024059282-A1 | IMPROVED POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024047248-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-03-07 | — | — | WO | disclosed |
| US-20230255989-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | DSM NUTRITIONAL PRODUCTS LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230190720-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | KAHRS, Bjoern Colin (CH) | 2023-06-22 | — | — | US | disclosed |
| WO-2023025722-A1 | METHODS FOR IMPROVING GUT MICROBIOTA DIVERSITY | Société des Produits Nestlé S.A. (CH) | 2023-03-02 | — | — | WO | disclosed |
| US-11484530-B2 | Pharmaceutical compositions comprising the PPAR agonist INT-131 and Nrf2 activators | Kahrs, Bjoern Colin (CH) | 2022-11-01 | — | — | US | disclosed |
| US-20220168384-A1 | Anti-Bacterial Combination Therapy | MCMASTER UNIVERSITY (CA) | 2022-06-02 | — | — | US | disclosed |
| US-20220125766-A1 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | MAGGIES PEARL LLC (US) | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240423967-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | PPARG, PPARA, PPARD | KDM4E 3011/4885HSD17B10 1640/4885ALDH1A1 838/4885 |
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | HBB, HBZ, HBG1 | KDM4E 1499/4885HSD17B10 817/4885ALDH1A1 382/4885 |
| US-11484530-B2 | Pharmaceutical compositions comprising the PPAR agonist INT-131 and Nrf2 activators | PPARG, PPARA, PPARD | KDM4E 4211/4885HSD17B10 1945/4885ALDH1A1 1177/4885 |
| US-20220125766-A1 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | MAN1B1, MAN2B1, GAA | KDM4E 3915/4885HSD17B10 487/4885ALDH1A1 1692/4885 |
| US-20220168384-A1 | Anti-Bacterial Combination Therapy | TST, SLC11A2, HAMP | KDM4E 4127/4885HSD17B10 2947/4885ALDH1A1 4659/4885 |
| US-20230190720-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | PPARG, PPARA, PPARD | KDM4E 3011/4885HSD17B10 1640/4885ALDH1A1 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.